secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001193125-23-255878
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127
--------------------------------------------------------------------------------

- RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.
- RMC-6236 demonstrates dose-dependent exposure and ctDNA reductions across NSCLC, PDAC, and multiple KRAS mutations.
- RMC-6291 achieves 50% ORR in NSCLC (prior G12Ci) and 43% in G12Ci-naïve; 40% ORR in CRC with 80% DCR.
- RMC-6291 safety includes 25% QTc prolongation (11% Grade 3) but no cardiac sequelae or hepatotoxicity signal.
- RMC-5127, an oral covalent tri-complex inhibitor of KRAS G12V (ON), selected as a development candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/0001193125-23-255878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/d566894d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-255878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer